No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.
Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.
The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.
The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.
Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.
Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.
Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.
Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.
Israeli drugmaker Teva Pharmaceutical Industries reported third-quarter profit that exceeded analyst expectations, driven by strong sales of three branded medicines that offset declines in generic drugs. The company raised its full-year 2026 revenue estimates following the results.
The European Medicines Agency has begun a safety review of Deanxit, a depression and anxiety medication made by Danish drugmaker H Lundbeck, following reports of serious neurological and psychiatric side effects.
The US FDA warned Amgen that a promotional video for its colorectal cancer drug Vectibix was misleading because it highlighted benefits while failing to adequately disclose serious safety risks and patient limitations. The warning letter was issued on Tuesday.
Indian drugmaker Cipla reported second-quarter earnings that missed profit expectations due to weakness in its US business, causing its shares to decline. The disappointing results reflect challenges in the company's American operations.
Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.
Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.
China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.
AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.
Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.
Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.
Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.
Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.
Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.
Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.
Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.
Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.
Syndax Pharmaceuticals discontinued development of Niktimvo for idiopathic pulmonary fibrosis after a mid-stage trial failed to meet its primary endpoint. The company's shares fell 17% in extended trading following the announcement.
Merck has discontinued Recarbrio, a crucial antibiotic used to treat drug-resistant infections, raising concerns among health experts about the availability of treatments for superbug resistance at a time when antimicrobial resistance remains a growing public health threat.
Kodiak Sciences announced that both investigational therapies, Zenkuda (tarcocimab tedromer) and KSI-501, met their primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, matching the performance of Regeneron's Eylea at one year. The company's stock surged over 65% in premarket trading following the announcement.
Amgen reported positive Phase 3 results for dazodalibep in moderate-to-severe Sjögren's disease, a chronic autoimmune condition with no currently approved therapies. The drug was acquired through Amgen's $28 billion Horizon Therapeutics buyout.
Vertex Pharmaceuticals announced positive results from its phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD), including patients with modest proteinuria and those with type 2 diabetes. The company is positioning the drug for a broad kidney disease label ahead of a key readout next year.
Novo Nordisk CEO Mike Doustdar told Reuters that oral weight-loss medications could represent up to half of the global obesity drug market by 2030, as the Danish drugmaker positions itself for a shift toward pill-based treatments alongside its injectable GLP-1 drugs.
President Trump announced he will demand pharmaceutical companies separate combined vaccines into individual doses, one day after Health Secretary Robert F. Kennedy Jr. told an anti-vaccine conference that vaccine skeptics have a 'friend at the White House.'
A Texas judge approved a wind-down bankruptcy plan for CVS Health subsidiary Omnicare LLC following the sale of its business operations for $250 million and resolution of a nearly $1 billion judgment related to improperly dispensing prescription drugs.
Pfizer is targeting air traffic control agencies in Poland and Romania to enforce a Belgian court ruling ordering the two countries to accept €1.9 billion worth of COVID-19 vaccines they refused to take delivery of after pandemic-era demand waned.
The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.
The CEO of Swiss pharmaceutical company Sandoz cautioned that President Donald Trump's threatened tariffs on generic drugs would ultimately be paid by American patients, as manufacturers could pass increased costs onto consumers.
AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.
The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.
Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.
Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.
Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.
Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.
A new ICER analysis found that net launch prices for new medicines spiked significantly between 2022 and 2025, with two-thirds of new drugs priced above cost-effectiveness guidelines. About a quarter of drugs launched in the most recent year had annual net prices exceeding $500,000.
Spanish pharmaceutical company Grifols has temporarily halted plasma donations at all 16 of its Canadian clinics following the deaths of two donors and a government investigation into potential unsafe practices at the for-profit facilities.
Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.
Hims & Hers Health reported a wider-than-expected second-quarter loss as the telehealth company's shift to branded weight-loss drugs drove up costs, sending shares down 6% in extended trading. The company plans to enter the peptides market before year-end.
Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.
Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.
Otsuka announced two-year Phase 3 VISIONARY trial results showing VOYXACT (sibeprenlimab-szsi) stabilized kidney function decline in IgA nephropathy patients, with annual eGFR slope of +0.3 versus -4.2 for placebo. Separately, BioNTech lowered its 2026 revenue guidance by €400 million to €1.6-1.9 billion due to declining COVID-19 vaccine demand.
Novo Nordisk reported quarterly results that beat expectations and raised guidance, but shares fell as investors remained concerned about the company's path to sustainable growth amid increasing competition in the obesity drug market.
Merck's anti-TL1A antibody from its 2023 Prometheus Biosciences acquisition delivered positive mid-stage results in hidradenitis suppurativa but failed to meet endpoints in a rare lung disease trial. The company disclosed the mixed Phase 2 results alongside its second-quarter earnings.
Merck beat second-quarter estimates and boosted its 2026 sales forecast after strong demand for newer drugs like Winrevair helped drive revenues higher, though the company cut profit guidance due to deal-related charges.
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a combined company with approximately $2.2 billion in annual revenue and a portfolio of 11 commercialized medicines focused on neurological, psychiatric, and addiction-related conditions. The deal, described as a merger of equals, is expected to generate $125 million in cost savings.
AstraZeneca is reportedly in discussions with Bristol Myers Squibb regarding a potential $400 billion merger, which would create one of the largest pharmaceutical companies globally and reshape the cancer treatment industry.
GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.
The European Medicines Agency recommended withdrawing marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing allegedly incorrect and misleading data used in the approval process and lack of benefits outweighing risks.
CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.
New ethics disclosures reveal President Trump purchased stock in Eli Lilly and an injectable device manufacturer while his health agencies implemented policies benefiting these companies' obesity drug products.
Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.
Americans are expected to spend more than $1 trillion on prescription drugs in 2026, according to a new report from the American Society of Health-System Pharmacists. The surge is largely attributed to the growing popularity of GLP-1 weight-loss drugs.
Bipartisan efforts are emerging at federal and state levels to regulate pharmacy benefit managers (PBMs), with proposals including barring companies from owning both PBMs and retail pharmacies. Two states have already enacted such restrictions, while federal legislation has gained support from both conservative Republicans and progressive Democrats.